Group B meningococcal recombinant variant fusion protein, manufacturing method and application
By preparing the OpcA-NHBA variant fusion protein, the limitations of the protection range and safety issues of existing group B meningococcal vaccines at home and abroad have been resolved, achieving a highly efficient and broad-spectrum vaccine protection effect.
Patent Information
- Application Number
- CN202510305731.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing group B meningococcal vaccines have limitations in their protection range both domestically and internationally, are complex to manufacture and costly, and have safety issues when used in China. They cannot effectively provide broad-spectrum protection against prevalent strains in China.
A recombinant protein from group B meningococcus, specifically an OpcA-NHBA variant fusion protein, was developed. The OpcA-NHBA variant fusion protein was prepared using an Escherichia coli expression system through plasmid construction, expression, and purification techniques, and a multi-step purification process was employed to obtain high-purity protein for vaccine preparation.
Animal experiments have shown that the recombinant OpcA-NHBA variant fusion protein can induce a high level of specific antibody response, providing effective protection against diseases caused by group B meningococcus, with a bactericidal rate of over 50%.
Smart Images

Figure CN123106916A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, and more specifically, to a group B meningococcal recombinant variant fusion protein, its manufacturing method, and its application. Background Technology
[0002] Neisseria meningitidis (Nm) was discovered in 1887 by Weichselbaum in the cerebrospinal fluid of patients with meningitis. Neisseria meningitidis is a Gram-negative bacterium, a member of the Neisseriaceae family of bacteria, and is an aerobic diplococcus, either encapsulated or unencapsulated, and is kidney-shaped or coffee bean-shaped.
[0003] Humans are currently considered the only natural host for meningococci. Identified meningococci can be divided into 13 serogroups, with serogroups A, B, C, W, X, and Y being the most common pathogenic to humans. Meningococci invade the host with high levels of variant antigens, evading both innate and adaptive immune responses. They enter the bloodstream by crossing the nasopharyngeal epithelium, leading to invasive meningococcal disease (IMD). IMD caused by meningococcal infection typically presents as meningitis or sepsis, or both simultaneously. A small number of patients may also exhibit symptoms such as pneumonia, purulent arthritis, and pericarditis. Globally, the incidence of IMD shows a strong geographic correlation, meaning it tends to recur and persist within a specific geographic area over a long period. IMD is characterized by a high mortality rate, and survivors may suffer severe sequelae, placing a significant economic burden on their families and reducing the quality of life for both the patient and their family members.
[0004] Meningococcal vaccines can be divided into two categories based on their antigenic components: capsular polysaccharide vaccines and protein-based vaccines. Meningococcal capsular polysaccharides from serogroups A, C, Y, and W135 have good antigenicity and can be used to prepare vaccines. However, the polysaccharide capsules of serogroup B meningococci lack immunogenicity, and vaccine development for them is mainly based on outermembrane vesicles (OMVs) and recombinant proteins. OMV vaccines extract natural protein components from bacterial outermembrane vesicles, including various outermembrane proteins, lipopolysaccharides, and other bacterial components, resulting in a broad antigenic spectrum. However, the OMV protein varies considerably among different strains, limiting the vaccine's protection to specific strains or regionally prevalent strains. Furthermore, the preparation of OMV vaccines requires bacterial culture, inactivation, extraction of outermembrane vesicles, and purification, making the process complex and costly. Additionally, residual lipopolysaccharides and other components may remain in the OMV, requiring further detoxification to reduce adverse reactions. The corresponding technologies disclosed in patent applications with application numbers 201410200898.7, 201410342886.8, 201510373194.4, 202010212354.8, and 201810880033.8 are examples of this. Furthermore, the application of recombinant protein vaccine technology allows for optimized antigen design targeting key conserved regions, enhanced cross-protection, standardized production processes, and high stability. As can be seen from the comparison, recombinant protein technology, due to its advantages of high efficiency, controllability, and broad-spectrum protection, is gradually becoming the mainstream direction for MenB vaccine development. The corresponding technologies disclosed in patents with application numbers 201911087155.2, 201911087614.7, 201510240635.3, 201911087686.1, 201711073721.5, 201610579059.X, and 202010186499.5.
[0005] In China, no group B meningococcal vaccines have been approved for marketing. Due to the complexity of the research and development technology, there are currently very few companies developing group B meningococcal vaccines. Two group B meningococcal vaccines have been approved for marketing abroad: Pfizer's rLP2086 (Trumenba) and GlaxoSmithKline's 4CMenB (Bexsero) vaccine, but neither has been launched in China. rLP2086 is a bivalent vaccine containing two lipid variants of the factor H binding protein (fHbp variants 1.55 and 3.45), with a single vaccine component. 4CMenB is a multi-component formulation composed of three main recombinant antigens: fHbp (variant 1.1) fused with the genome-derived Neisseria gonorrhoeae antigen (GNA) 2091, Neisseria gonorrhoeae heparin-binding antigen (NHBA, peptide 2) fused with GNA1030, and Neisseria gonorrhoeae adhesin a (NadA, variant 3). In addition to these three proteins, the vaccine also includes OMV extracted from the New Zealand-circulating strain (NZ98 / 254), and the antigens include multiple components such as OpcA, PorA, and PorB. However, because group B meningococci not only have strong geographical correlations, but also because the prevalent strains differ between countries, foreign vaccines may not necessarily protect against domestic strains. Furthermore, the GSK 4CMenB (Bexsero) vaccine contains components of outer membrane vesicles, which may contain residual lipopolysaccharides and other components, posing safety concerns. These factors contribute to the shortcomings of existing marketed group B meningococcal vaccines.
[0006] The predominant clonal groups of serogroup B meningococci in my country differ from those in the 4CMenB vaccine. Furthermore, only 7.6% of serogroup B meningococcal strains in my country contain NadA protein, indicating a very low prevalence. Therefore, NadA protein is not recommended as a candidate vaccine for serogroup B meningococci. my country should develop a serogroup B meningococcal vaccine based on the characteristics of its prevalent strains. In most serogroup B strains isolated in China, NHBA protein is ubiquitous. Different NHBA variants exhibit similarities and can induce cross-protective antibodies. The NHBA (peptide 20) used in this study belongs to cluster 2, while the NHBA (peptide 2) in the GSK vaccine belongs to cluster 1. Additionally, OpcA protein is widely present in various meningococcal strains. As a vaccine antigen component, it can provide protection against various serogroups of meningococci, including A / B / C / Y / W135, exhibiting broad-spectrum protection. Simultaneously, this protein possesses high immunogenicity in humans, stimulating the immune system to produce bactericidal antibodies. Summary of the Invention
[0007] This invention provides a group B meningococcal recombinant variant fusion protein, its manufacturing method, and its application, aiming to address the problems mentioned in the background art.
[0008] A recombinant protein from group B meningococcus, including the OpcA-NHBA variant fusion protein.
[0009] As an improvement to the aforementioned group B meningococcal recombinant protein, the OpcA-NHBA variant fusion protein is shown in sequence number 1 of the sequence listing.
[0010] As a further improvement to the group B meningococcal recombinant protein described above, the OpcA-NHBA variant fusion protein is tagged with purification.
[0011] As a further improvement to the group B meningococcal recombinant protein described above, the purification tag is a 6*his tag; the OpcA-NHBA variant fusion protein with the 6*his tag is shown in sequence number 2 of the sequence listing.
[0012] A method for manufacturing a recombinant protein from group B meningococcus includes the following steps: plasmid construction and expression of the recombinant OpcA-NHBA variant fusion protein; purification of the recombinant OpcA-NHBA variant fusion protein.
[0013] As an improvement to the method for manufacturing a recombinant protein of group B meningococcus, the plasmid construction and expression of the recombinant OpcA-NHBA variant fusion protein include the following steps: PCR amplification is performed using PCR amplification technology; the PCR amplification product is taken and subjected to 1% agarose gel electrophoresis at 90V-120V for 30min; the PCR product and vector pET28a are digested with BamHI and HindIII, recovered from the gel, and ligated with T4 DNA ligase; the recombinant plasmid is transformed into competent Escherichia coli cells, positive recombinants are screened, and the recombinant bacteria are inoculated into LB liquid medium containing kanamycin sulfate and cultured at 37℃ for 4 hours to obtain the target protein.
[0014] As a further improvement to the method for manufacturing a group B meningococcal recombinant protein, the Escherichia coli strain is BL21(DE3); the OpcA-NHBA variant fusion protein is expressed as an inclusion body.
[0015] As a further improvement to the method for manufacturing a group B meningococcal recombinant protein, the purification of the recombinant OpcA-NHBA variant fusion protein includes the following steps: engineered bacteria expressing the recombinant OpcA-NHBA variant fusion protein are obtained by culturing in a fermenter and stored at -70℃; the bacterial cells are suspended in a 0.9% physiological saline buffer solution in equal proportions and lysed under high pressure; the washed inclusion bodies are mixed with the inclusion body lysate in equal proportions, the supernatant is collected, filtered through a 0.22µm filter, and primary purification, intermediate purification, and final purification are performed respectively.
[0016] As a further improvement to the method for manufacturing a group B meningococcal recombinant protein, the primary purification uses a Diamond Q Mustang anion exchange column and elutes with NaCl; the intermediate purification uses a Ni-Charged Resign affinity chromatography column and elutes with imidazole; and the final purification uses an SP Bestarose FF affinity chromatography column and elutes with NaCl.
[0017] As a further improvement to the method for manufacturing a group B meningococcal recombinant protein, the concentration of NaCl elution buffer is 200 mmol / L in the primary purification; the concentration of imidazole elution buffer is 200 mmol / L in the intermediate purification; and the concentration of NaCl elution buffer is 500 mmol / L in the final purification.
[0018] Application of a recombinant protein from group B meningococcus in group B meningococcal vaccine formulation.
[0019] An adjuvant for a group B meningococcal vaccine formulation includes one or more combinations of aluminum hydroxide, aluminum phosphate, CpG, picaridin, MPL, QS-21, and squalene.
[0020] In summary, the beneficial effects of this invention are:
[0021] To develop a vaccine against the prevalent serogroup B meningococcus in China, this study utilized recombinant genetic engineering technology to express both the serogroup B NHBA variant protein separately and the serogroup B recombinant fusion OpcA-NHBA variant protein. Due to the low expression level of the serogroup B NHBA variant protein expressed alone, only the significantly expressed serogroup B recombinant fusion OpcA-NHBA variant protein was purified and evaluated in animal experiments. The results showed that immunization of animals with the recombinant OpcA-NHBA variant fusion protein produced high levels of specific antibodies, achieving a bactericidal rate of over 50% at a serum dilution of 1:5. As a potential candidate vaccine for the brain, it could provide effective protection against meningitis, sepsis, and pericarditis caused by serogroup B meningococcus. Attached Figure Description
[0022] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained from these drawings without creative effort.
[0023] Figure 1These are the PCR amplification results of plasmid OpcA-NHBA in the embodiments of the present invention (M:DL2000; 1: plasmid OpcA-NHBA; 2: plasmid OpcA-NHBA);
[0024] Figure 2 This is an example of an OpcA-NHBA restriction enzyme digestion identification diagram (M: DL10000; 1: OpcA-NHBA-pET28 original plasmid; 2: OpcA-NHBA-pET28 restriction enzyme digestion diagram).
[0025] Figure 3 This is a diagram of OpcA-NHBA protein induction expression in an embodiment of the present invention (M: protein Maker; 1: before OpcA-NHBA induction; 2: after OpcA-NHBA induction).
[0026] Figure 4 This is a Western Blot image of OpcA-NHBA in an embodiment of the present invention (M: protein marker; 1: before OpcA-NHBA induction; 2: after OpcA-NHBA induction);
[0027] Figure 5 This is an SDS-PAGE image of the recombinant fusion protein OpcA-NHBA cationic purification in an embodiment of the present invention (M: protein marker; 1: flow-through; 2: 500mM NaCl elution buffer; 3: NaOH alkaline wash). Detailed Implementation
[0028] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0029] Example 1: Plasmid construction and expression of recombinant OpcA-NHBA variant fusion protein
[0030] Escherichia coli BL21(DE3) (purchased from Sangon Biotech) and pET28a (purchased from General Biotechnology) were used for PCR amplification using OpcA-NHBA (purchased from General Biotechnology) as a template. After the reaction, the PCR amplification products were subjected to 1% agarose gel electrophoresis at 90V-120V for 30 min. The results were then observed using a gel imaging system. The product fragment size was approximately 2028bp, consistent with the expected result. The results are shown in the figure below. Figure 1 .
[0031] To obtain the recombinant vector OpcA-NHBA, the PCR product of OpcA-NHBA and the vector pET28a were digested with BamHI and HindIII, recovered from the gel, and ligated using T4 DNA ligase. The fragments were then digested with the same restriction enzymes for identification. The large fragment was approximately 5300 bp, and the small fragment was approximately 2000 bp, consistent with the expected results. (See attached figure). Figure 2 .
[0032] To obtain the target OpcA-NHBA variant fusion protein, its recombinant plasmid was transformed into *E. coli* BL(DE3) competent cells. Positive recombinants were screened, and the recombinant bacteria were inoculated into LB liquid medium containing kanamycin sulfate and cultured at 37°C for 4 hours. The target protein, approximately 76.4 kDa, was obtained, consistent with the expected result. (See attached table). Figure 3 and Figure 4 .
[0033] To determine the expression form of the target protein OpcA-NHBA variant fusion protein, the induced bacterial culture was used to disrupt the bacteria by sonication 30-50 times (6 seconds of operation followed by 4 seconds of rest). The precipitate and supernatant were both analyzed by SDS-PAGE electrophoresis, which confirmed that the expression form was inclusion bodies.
[0034] Example 2: Purification of recombinant OpcA-NHBA variant fusion protein
[0035] Engineered bacteria expressing the recombinant OpcA-NHBA variant fusion protein were obtained from fermenter culture and stored at -70℃. The highly efficient expressed bacterial cells were suspended in 0.9% physiological saline buffer and homogenized under high pressure using a Danish APV-1000 high-pressure homogenizer. After homogenization, a small amount of bacterial solution was smeared, stained, and the cell integrity was observed under a microscope to ensure complete cell disruption. Finally, the washed inclusion bodies were mixed with inclusion body lysis solution in equal proportions, and the supernatant was collected and filtered through a 0.22 μm filter as the raw material for the next purification step.
[0036] Two types of chromatography columns, Diamond Q Mustang and Diamond Q (purchased from BorgLyn), were connected to the AutoDesk Pure chromatography system to explore purification conditions for the target protein under the same conditions. The packing material with the best purification performance was selected for scale-up. The Diamond Q Mustang anion exchange column was used for primary purification, and the purification conditions for the target protein were explored using 1 mol / L NaCl. A NaCl gradient elution was employed, and it was confirmed that the target protein was expressed in a 200 mmol / L NaCl elution buffer.
[0037] Two types of chromatography columns, Ni-Charged Resign and MC60-Ni Excel (purchased from BorgL Optoelectronics), were connected to the AutoDesk Pure chromatography system to explore purification conditions for the target protein under the same conditions. The column with the best purification performance was selected for scale-up. Ni-Charged Resign affinity chromatography was used for intermediate purification. Purification conditions for the target protein were explored using 1 mol / L imidazole, employing an imidazole gradient elution. It was confirmed that the target protein was expressed in a 200 mmol / L imidazole elution buffer.
[0038] Two chromatography columns, SP Bestarose FF and UniGel-80SP (purchased from BorgLone), were connected to the AutoDesk Pure chromatography system to explore purification conditions for the target protein under identical conditions. The column with the best purification performance was selected for scale-up. SP Bestarose FF affinity chromatography was chosen for final purification. Purification conditions for the target protein were explored using 1 mol / L NaCl, employing a NaCl gradient elution. It was confirmed that the target protein was expressed in a 500 mmol / L NaCl elution buffer. Figure 5 .
[0039] The OpcA-NHBA variant fusion protein of the present invention is shown in sequence number 1 of the sequence listing. During the purification process described above, the OpcA-NHBA variant fusion protein with a 6*his tag is preferred, as shown in sequence number 2 of the sequence listing.
[0040] Example 3: Refolding of recombinant OpcA-NHBA variant fusion protein and preparation of candidate vaccine
[0041] Prepare inclusion body samples of the OpcA-NHBA variant fusion protein after cationic purification. The sample concentration should not be too high. Place the sample in a dialysis bag and refold it in buffer for 24–36 hours.
[0042] Based on the size of the target protein, select an appropriate ultrafiltration concentration tube to concentrate the target protein through ultrafiltration until the protein concentration reaches 1 mg / mL. Then, aliquot the candidate vaccine into equal volumes, with each vaccine containing 25 μg of the target protein.
[0043] Example 4: Determination of the immunogenicity of recombinant OpcA-NHBA variant fusion protein
[0044] The recombinant OpcA-NHBA variant fusion protein, which was prepared by our company, was mixed with adjuvants. The aluminum hydroxide adjuvant and CPG adjuvant were prepared by our company, and the Pica adjuvant was purchased from Guangdong Nanguo Pharmaceutical Co., Ltd. BALB / c mice (purchased from Hangzhou Qizhen Experimental Animal Technology Co., Ltd.) were immunized three times, with each immunization 15 days apart. One week after the last booster immunization, blood was collected from the tail vein of the mice for ELISA to determine antibody titer and serum bactericidal experiment.
[0045] ELISA results showed that the IgG levels in the antigen and double adjuvant group were higher than those in the antigen and single adjuvant group, which in turn were higher than those in the antigen-only group, which were higher than those in the control and blank groups. The use of adjuvants indeed improved antibody specificity. Serum bactericidal experiments showed that, under complement-mediated action and with an immune serum dilution ratio of 1:5, serum from each immunization group resulted in the death of more than 50% of bacterial strains, indicating that the antibodies all possessed a certain specific ability to kill group B meningococci. The serum antibodies from the blank and control groups, however, did not exhibit this killing ability. The experimental results are shown in Tables 1-1 and 1-2.
[0046]
[0047] Table 1-1 Serum IgG antibody titer of mice after the third immunization, as determined by ELLSA assay.
[0048]
[0049] Table 1-2 Serum bactericidal results after the third immunization
[0050] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the invention by those skilled in the art. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the invention should be included within the scope of protection of the invention.
Claims
1. A group B meningococcal recombinant protein, characterized in that, Including the OpcA-NHBA variant fusion protein.
2. The group B meningococcal recombinant protein according to claim 1, characterized in that, The OpcA-NHBA variant fusion protein is shown in sequence number 1 of the sequence listing.
3. The recombinant protein of group B meningococcus according to claim 1, characterized in that, The OpcA-NHBA variant fusion protein is labeled with a purification tag.
4. The recombinant protein of group B meningococcus according to claim 3, characterized in that, The purification tag is a 6*his tag; The OpcA-NHBA variant fusion protein with the 6*his tag is shown in sequence number 2 of the sequence listing.
5. The process for the manufacture of a group B meningococcal recombinant protein as claimed in claim 1, wherein, Includes the following steps: The plasmid construction and expression of the recombinant OpcA-NHBA mutant fusion protein are as follows: PCR amplification is performed using PCR amplification technology; Take the PCR amplification products and perform electrophoresis on a 1% agarose gel at 90V-120V for 30 minutes. The PCR product and vector pET28a were digested with BamHI and HindII, recovered by gel, and ligated with T4 DNA ligase. The recombinant plasmid was transformed into competent E. coli cells, positive recombinants were screened, and the recombinant bacteria were inoculated into LB liquid medium containing kanamycin sulfate and cultured at 37°C for 4 hours to obtain the target protein. The purification steps for the recombinant OpcA-NHBA mutant fusion protein are as follows: Engineered bacteria expressing recombinant OpcA-NHBA variant fusion protein were obtained by fermentation and stored at -70℃; The bacterial cells were suspended in a 0.9% physiological saline buffer solution and then destroyed under high pressure. The washed inclusion bodies were mixed with the inclusion body solution in equal proportions, and the supernatant was collected and filtered through a 0.22 μm filter for primary purification, intermediate purification and final purification.
6. The process for the manufacture of a group B meningococcal recombinant protein as claimed in claim 5, wherein, The Escherichia coli strain was BL21(DE3); The OpcA-NHBA variant fusion protein is expressed as an inclusion body.
7. The process for the manufacture of a group B meningococcal recombinant protein as claimed in claim 6, wherein, The primary purification was performed using a Diamond Q Mustang anion exchange column, eluted with NaCl eluent. The intermediate purification was performed using a Ni-Charged Resign affinity chromatography column and eluted with imidazole elution buffer. The final purification was performed using an SP Bestarose FF affinity chromatography column, eluted with NaCl eluent.
8. The process for the manufacture of a group B meningococcal recombinant protein as claimed in claim 5, wherein, In the primary purification, the concentration of the NaCl eluent is 200 mmol / L; In the intermediate purification, the concentration of the imidazole elution buffer was 200 mmol / L; In the final purification, the concentration of NaCl eluent is 500 mmol / L.
9. The application of the recombinant protein of group B meningococcus according to claim 1 in group B meningococcal vaccine formulation.
10. An adjuvant for a Group B meningococcal vaccine preparation according to claim 9, characterised in that, It includes one or more of the following: aluminum hydroxide, aluminum phosphate, CpG, PIC, MPL, QS-21, and squalene.
Citation Information
Patent Citations
ABC group meningococcal combined vaccine and its preparation method
CN104001166B
Multivalent group B meningococcal protein vaccine and preparation method thereof
CN104127869A
B-group epidemic neisseria meningitidis recombinant protein vaccine and preparing method thereof
CN104888209A
Novel ACYW135 meningococcal conjugate vaccine and preparation method thereof
CN104998255A
Group ABC meningococcus combined vaccine and preparing method thereof
CN106215183A
